Randomized Clinical Stroke Trials in 2007

Meheroz H Rabadi*, 1, John P Blass2
1 Veterans Affairs Medical Center at Oklahoma University
2 Burke Medical Research Institute Weill Medical College of Cornell University, USA

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 2657
Abstract HTML Views: 2143
PDF Downloads: 685
Total Views/Downloads: 5485
Unique Statistics:

Full-Text HTML Views: 1156
Abstract HTML Views: 1314
PDF Downloads: 490
Total Views/Downloads: 2960

Creative Commons License
© Rabadi and Blass; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Veterans Affairs Medical Center, 921 NE 13th Street, Oklahoma City OK, USA; Tel: (405) 270- 0501 Extension 5298; Fax: (405) 270- 1504; E-mail:


This article reviews the randomized control trials (RCT’s) that were published in 2007 of emerging pharmacotherapies in patients with acute (≤ 2 weeks), sub-acute (2 to 12 weeks) and chronic (≥ 12 weeks) stroke. A Medline search generated 22 RCT’s in stroke in the year 2007 in the English language. These trials were primarily efficacy studies. These included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovascular disease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in Type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one FDA approved thrombolytic agent (r TPA); benefit of warfarin (an anticoagulant) in elderly patients with atrial fibrillation in the community; NXY (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a Calcium channel blocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage. Finally the role of non-pharmacotherapy like stents for patient’s with internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion and in vertebral artery stenosis.

Keywords: Randomized control trials, stroke, rehabilitation.